Cambridge, MA – According to filings with the U.S. Securities and Exchange Commission, Odyssey Therapeutics is raising $168,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Gary Glick played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Odyssey Therapeutics
Led by a team with an exceptional track record of success, we aim to deliver life-enhancing precision medicines to patients with cancer and inflammatory diseases. Together, we work with dedication and urgency, employing an integrated suite of cutting-edge technologies directed at molecular targets that hold the greatest promise to benefit patients. Our team of drug hunters and academic founders are experts in the pathophysiology of cancer and inflammatory disorders. Odyssey is leveraging this in-house intellectual capital not only to select targets but also define the therapeutic profile to have the greatest clinical benefit: we quickly identify relevant targets, devise pharmacological mechanisms of intervention to correct the disease, and optimize our candidates for efficient clinical development and real-world patient benefit.

To learn more about Odyssey Therapeutics, visit http://odysseytx.com/

Contact:
Gary Glick, President and Chief Executive Officer
212-841-1000
https://www.linkedin.com/in/gary-d-glick-71145015b/

SOURCE: http://www.intelligence360.io
Copyright (c) 2022 SI360 Inc. All rights reserved